SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients.
| Autor: | Ray EC; Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA., Boyd-Shiwarski CR; Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA., Liu P; Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.; Baylor Genetics, Houston, TX., Novacic D; Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Cassiman D; Department of Gastroenterology and Hepatology, University Hospitals, Leuven, Belgium. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Kidney medicine [Kidney Med] 2020 Apr 18; Vol. 2 (3), pp. 359-364. Date of Electronic Publication: 2020 Apr 18 (Print Publication: 2020). |
| DOI: | 10.1016/j.xkme.2020.01.010 |
| Abstrakt: | In patients with urinary magnesium wasting, oral and intravenous supplementation often fail to adequately improve serum magnesium levels. Glucose intolerance and diabetes mellitus frequently accompany hypomagnesemia. Clinical trials examining inhibitors of the type 2 sodium glucose cotransporter (SGLT2) show small but significant increases in serum magnesium levels in diabetic patients. This report describes dramatic improvement in serum magnesium levels and associated symptoms after initiating SGLT2 inhibitor therapy in 3 patients with refractory hypomagnesemia and diabetes. Each patient received a different SGLT2 inhibitor: canagliflozin, empagliflozin, or dapagliflozin. One patient discontinued daily intravenous magnesium supplements and exhibited higher serum magnesium levels than had been achieved by magnesium infusion. 2 of the 3 patients exhibited reduced urinary fractional excretion of magnesium, suggesting enhanced tubular reabsorption of magnesium. These observations demonstrate that SGLT2 inhibitors can improve the management of patients with otherwise intractable hypomagnesemia, representing a new tool in this challenging clinical disorder. (© 2020 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|